US: 1.646.568.9797 (24x5)
UK: 44.330.808.0580 (24x5)
Worldwide: 91.703.051.960 (24x7)
Abstract, Snapshot, Market Analysis & Market Definition: Phosphoinositide 3-Kinase (PI3K) Inhibitors Market PI3K inhibitors work by inhibiting PI3K enzymes, which helps in signaling the pathway for cellular functions such as growth control, metabolism, and translation initiation. There is extensive ongoing research on targeted therapies such as PI3K inhibitors with proven efficacy in oncology applications. 3-kinase (PI3K) inhibitors are a class of medicines are developed to inhibit one or more of the phosphoinositide 3-kinase enzymes. These enzymes form part of the PI3K/AKT/mTOR pathway, which is a pathway involved in cell growth and survival, as well as several other processes that are frequently activated in many cancers. By inhibiting these enzymes, PI3K inhibitors cause cell death, inhibit the proliferation of malignant cells, and interfere with several signaling pathways. PI3K inhibitors are usually given to treat certain cancers that have relapsed or are unresponsive to other cancer treatments. Typically, at least two other cancer treatments need to have been tried and been unsuccessful or not tolerated before PI3K inhibitors are given. Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K/Phosphatidylinositol-4,5-bisphosphate 3-kinase/phosphatidylinositide 3-kinase) inhibitor that was first developed by Bayer Healthcare Pharmaceuticals, Inc. The cost for Aliqopa(Copanlisib) intravenous powder for injection 60 mg is around $4,800 for a supply of 1 powder for injection. Aliqopa is available as a brand name drug only, a generic version is not yet available in the United States Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. Research around duvelisib showed that this agent is a potent inhibitor of both forms. Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018. The cost for Copiktra(Duvelisib) oral capsule 15 mg is around $12,900 for a supply of 56 capsules is available as a brand name drug only, a generic version is not yet available in the United States. Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). The cost for Zydelig(Idelalisib) oral tablet 100 mg is around $11,650 for a supply of 60 tablets. The significant R&D in the prevailing class of therapeutics has given rise to targeted therapies. In 2020, the global Phosphoinositide 3-Kinase (PI3K) Inhibitors market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. This report focuses on the global Phosphoinositide 3-Kinase (PI3K) Inhibitors status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Phosphoinositide 3-Kinase (PI3K) Inhibitors development in United States, Europe and China. Market Segmentation, Outlook & Regional Insights: Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Segmentation by Product Type: Breakdown of data from year 2015 to 2020 and forecast until 2026:
Segmentation by Application: Breakdown of data from year 2015 to 2020 and forecast until 2026:
- CLL - Chronic Iymphocytic Ieukemia
- FL - Follicular Iymphoma
- Other Indications
Market segment by Regions/Countries, this report covers
- Research Institutes and Research Institutions
Key Players, Recent Developments & Sector Viewpoints: Phosphoinositide 3-Kinase (PI3K) Inhibitors Market
- North America
- Asia Pacific
- Southeast Asia
- Central & South America
In October 2020, Novartis Europharm Limited received marketing authorization valid throughout the European Union for Piqray (active substance alpelisib) which is a cancer medicine used to treat postmenopausal women and men with breast cancer that is locally advanced or has spread to other parts of the body. Piqray can only be used when the cancer cells have receptors for certain hormones on their surface (HR-positive) and do not have large quantities of another receptor called HER2 (HER2-negative). The cancer cells must also have been shown to have a specific mutation (change) in the gene called PIK3CA. Piqray is used with the medicine fulvestrant. The active substance in Piqray, alpelisib, works by blocking the activity of the abnormal PI3K, thereby reducing the growth and spread of the cancer. Piqray used with fulvestrant increased the time before the disease got worse in patients with HR-positive and HER2-negative breast cancer that is advanced or has spread. Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. The cost for Piqray oral tablet (200 mg-50 mg) is around USD$17,000 for a supply of 60 tablets. Piqray is available as a brand name drug only, a generic version is not yet available. Key Insights Covered: Exhaustive Phosphoinositide 3-Kinase (PI3K) Inhibitors Market 1. Market size (sales, revenue and growth rate) of Phosphoinositide 3-Kinase (PI3K) Inhibitors industry. 2. Global major manufacturers' operating situation (sales, revenue, growth rate and gross margin) of Phosphoinositide 3-Kinase (PI3K) Inhibitors industry. 3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Phosphoinositide 3-Kinase (PI3K) Inhibitors industry. 4. Market size (sales, revenue) forecast by regions and countries from 2021 to 2026 of Phosphoinositide 3-Kinase (PI3K) Inhibitors industry. Research Methodology: Phosphoinositide 3-Kinase (PI3K) Inhibitors Market
- Bayer AG
- Gilead Sciences Inc.
- Novartis AG
- TG Therapeutics Inc.
- Verastem Inc.
- Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
- Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
- Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among others.
1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered 1.4 Market Analysis by Type 1.4.1 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Size Growth Rate by Type (2014-2025) 1.4.2 CLL - Chronic Iymphocytic Ieukemia 1.4.3 FL - Follicular Iymphoma 1.4.4 Other Indications 1.5 Market by Application 1.5.1 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Share by Application (2014-2025) 1.5.2 hospital | read more...